Which has stronger valuation and earnings, ARGX or BNTX?

argenex has higher revenue and earnings than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio argenex $4.25B 12.99 $1.29B $22.46 39.50 BioNTech $3.25B 7.11 -$1.29B -$5.88 N/A

Is ARGX or BNTX more profitable?

argenex has a net margin of 31.31% compared to BioNTech's net margin of -44.39%. argenex's return on equity of 44.37% beat BioNTech's return on equity. Company Net Margins Return on Equity Return on Assets argenex 31.31% 44.37% 37.55% BioNTech -44.39% -5.30% -4.62%

Does the media favor ARGX or BNTX?

In the previous week, argenex had 8 more articles in the media than BioNTech. MarketBeat recorded 12 mentions for argenex and 4 mentions for BioNTech. BioNTech's average media sentiment score of 1.23 beat argenex's score of 0.00 indicating that BioNTech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment argenex 0 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral BioNTech 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer BNTX or TAK?

BioNTech presently has a consensus price target of $129.56, suggesting a potential upside of 42.03%. Given BioNTech's stronger consensus rating and higher possible upside, equities analysts plainly believe BioNTech is more favorable than Takeda Pharmaceutical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioNTech 1 Sell rating(s) 4 Hold rating(s) 13 Buy rating(s) 1 Strong Buy rating(s) 2.74 Takeda Pharmaceutical 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50

Does the media prefer BNTX or TAK?

In the previous week, BioNTech and BioNTech both had 4 articles in the media. BioNTech's average media sentiment score of 1.23 beat Takeda Pharmaceutical's score of 0.12 indicating that BioNTech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioNTech 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Takeda Pharmaceutical 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to BNTX or TEVA?

In the previous week, Teva Pharmaceutical Industries had 11 more articles in the media than BioNTech. MarketBeat recorded 15 mentions for Teva Pharmaceutical Industries and 4 mentions for BioNTech. Teva Pharmaceutical Industries' average media sentiment score of 1.27 beat BioNTech's score of 1.23 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioNTech 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Teva Pharmaceutical Industries 11 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer BNTX or RVMD?

In the previous week, Revolution Medicines had 4 more articles in the media than BioNTech. MarketBeat recorded 8 mentions for Revolution Medicines and 4 mentions for BioNTech. BioNTech's average media sentiment score of 1.23 beat Revolution Medicines' score of 0.34 indicating that BioNTech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioNTech 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Revolution Medicines 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer BNTX or ONC?

In the previous week, BeOne Medicines had 9 more articles in the media than BioNTech. MarketBeat recorded 13 mentions for BeOne Medicines and 4 mentions for BioNTech. BioNTech's average media sentiment score of 1.23 beat BeOne Medicines' score of 0.18 indicating that BioNTech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioNTech 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BeOne Medicines 3 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

BioNTech (BNTX) Competitors

$91.22 +1.22 (+1.36%)

Closing price 06/26/2026 04:00 PM Eastern

Extended Trading

$90.75 -0.47 (-0.51%)

As of 06/26/2026 07:43 PM Eastern

Compare

BNTX vs. ARGX, TAK, TEVA, RVMD, and ONC

Should you buy BioNTech stock or one of its competitors? MarketBeat compares BioNTech with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with BioNTech include argenex (ARGX), Takeda Pharmaceutical (TAK), Teva Pharmaceutical Industries (TEVA), Revolution Medicines (RVMD), and BeOne Medicines (ONC). These companies are all part of the "pharmaceutical products" industry.

How does BioNTech compare to argenex?

argenex (NASDAQ:ARGX) and BioNTech (NASDAQ:BNTX) are both large-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, analyst recommendations, risk, profitability, valuation, earnings and dividends.

In the previous week, argenex had 8 more articles in the media than BioNTech. MarketBeat recorded 12 mentions for argenex and 4 mentions for BioNTech. BioNTech's average media sentiment score of 1.23 beat argenex's score of 0.00 indicating that BioNTech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
argenex	0 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral
BioNTech	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

argenex has a beta of 0.47, meaning that its stock price is 53% less volatile than the broader market. Comparatively, BioNTech has a beta of 1.33, meaning that its stock price is 33% more volatile than the broader market.

argenex presently has a consensus price target of $1,023.39, indicating a potential upside of 15.35%. BioNTech has a consensus price target of $129.56, indicating a potential upside of 42.03%. Given BioNTech's higher probable upside, analysts plainly believe BioNTech is more favorable than argenex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
argenex	0 Sell rating(s)	4 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.92
BioNTech	1 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.74

argenex has a net margin of 31.31% compared to BioNTech's net margin of -44.39%. argenex's return on equity of 44.37% beat BioNTech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
argenex	31.31%	44.37%	37.55%
BioNTech	-44.39%	-5.30%	-4.62%

argenex has higher revenue and earnings than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
argenex	$4.25B	12.99	$1.29B	$22.46	39.50
BioNTech	$3.25B	7.11	-$1.29B	-$5.88	N/A

60.3% of argenex shares are owned by institutional investors. Comparatively, 15.5% of BioNTech shares are owned by institutional investors. 2.4% of argenex shares are owned by company insiders. Comparatively, 19.2% of BioNTech shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

argenex beats BioNTech on 13 of the 17 factors compared between the two stocks.

How does BioNTech compare to Takeda Pharmaceutical?

BioNTech (NASDAQ:BNTX) and Takeda Pharmaceutical (NYSE:TAK) are both large-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, institutional ownership, dividends, risk, earnings, media sentiment, analyst recommendations and profitability.

BioNTech presently has a consensus price target of $129.56, suggesting a potential upside of 42.03%. Given BioNTech's stronger consensus rating and higher possible upside, equities analysts plainly believe BioNTech is more favorable than Takeda Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioNTech	1 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.74
Takeda Pharmaceutical	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.50

Takeda Pharmaceutical has higher revenue and earnings than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioNTech	$3.25B	7.11	-$1.29B	-$5.88	N/A
Takeda Pharmaceutical	$28.32B	1.79	-$1.01B	$0.39	40.81

BioNTech has a beta of 1.33, indicating that its stock price is 33% more volatile than the broader market. Comparatively, Takeda Pharmaceutical has a beta of -0.07, indicating that its stock price is 107% less volatile than the broader market.

Takeda Pharmaceutical has a net margin of 4.31% compared to BioNTech's net margin of -44.39%. Takeda Pharmaceutical's return on equity of 11.20% beat BioNTech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioNTech	-44.39%	-5.30%	-4.62%
Takeda Pharmaceutical	4.31%	11.20%	5.48%

15.5% of BioNTech shares are held by institutional investors. Comparatively, 9.2% of Takeda Pharmaceutical shares are held by institutional investors. 19.2% of BioNTech shares are held by insiders. Comparatively, 0.0% of Takeda Pharmaceutical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, BioNTech and BioNTech both had 4 articles in the media. BioNTech's average media sentiment score of 1.23 beat Takeda Pharmaceutical's score of 0.12 indicating that BioNTech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioNTech	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Takeda Pharmaceutical	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

BioNTech beats Takeda Pharmaceutical on 9 of the 16 factors compared between the two stocks.

How does BioNTech compare to Teva Pharmaceutical Industries?

BioNTech (NASDAQ:BNTX) and Teva Pharmaceutical Industries (NYSE:TEVA) are both large-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, earnings, risk, valuation, profitability, institutional ownership, dividends and analyst recommendations.

Teva Pharmaceutical Industries has a net margin of 9.01% compared to BioNTech's net margin of -44.39%. Teva Pharmaceutical Industries' return on equity of 43.53% beat BioNTech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioNTech	-44.39%	-5.30%	-4.62%
Teva Pharmaceutical Industries	9.01%	43.53%	8.19%

BioNTech has a beta of 1.33, suggesting that its share price is 33% more volatile than the broader market. Comparatively, Teva Pharmaceutical Industries has a beta of 0.84, suggesting that its share price is 16% less volatile than the broader market.

In the previous week, Teva Pharmaceutical Industries had 11 more articles in the media than BioNTech. MarketBeat recorded 15 mentions for Teva Pharmaceutical Industries and 4 mentions for BioNTech. Teva Pharmaceutical Industries' average media sentiment score of 1.27 beat BioNTech's score of 1.23 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioNTech	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Teva Pharmaceutical Industries	11 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

BioNTech presently has a consensus target price of $129.56, suggesting a potential upside of 42.03%. Teva Pharmaceutical Industries has a consensus target price of $41.78, suggesting a potential upside of 25.68%. Given BioNTech's higher possible upside, equities analysts plainly believe BioNTech is more favorable than Teva Pharmaceutical Industries.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioNTech	1 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.74
Teva Pharmaceutical Industries	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80

Teva Pharmaceutical Industries has higher revenue and earnings than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than Teva Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioNTech	$3.25B	7.11	-$1.29B	-$5.88	N/A
Teva Pharmaceutical Industries	$17.26B	2.21	$1.41B	$1.33	24.99

15.5% of BioNTech shares are owned by institutional investors. Comparatively, 54.1% of Teva Pharmaceutical Industries shares are owned by institutional investors. 19.2% of BioNTech shares are owned by insiders. Comparatively, 0.5% of Teva Pharmaceutical Industries shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Teva Pharmaceutical Industries beats BioNTech on 11 of the 17 factors compared between the two stocks.

How does BioNTech compare to Revolution Medicines?

BioNTech (NASDAQ:BNTX) and Revolution Medicines (NASDAQ:RVMD) are both large-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, media sentiment, valuation, profitability, dividends and institutional ownership.

15.5% of BioNTech shares are held by institutional investors. Comparatively, 94.3% of Revolution Medicines shares are held by institutional investors. 19.2% of BioNTech shares are held by insiders. Comparatively, 7.6% of Revolution Medicines shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Revolution Medicines has a net margin of 0.00% compared to BioNTech's net margin of -44.39%. BioNTech's return on equity of -5.30% beat Revolution Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioNTech	-44.39%	-5.30%	-4.62%
Revolution Medicines	N/A	-83.22%	-59.06%

BioNTech currently has a consensus target price of $129.56, indicating a potential upside of 42.03%. Revolution Medicines has a consensus target price of $123.72, indicating a potential downside of 32.05%. Given BioNTech's higher possible upside, equities research analysts plainly believe BioNTech is more favorable than Revolution Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioNTech	1 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.74
Revolution Medicines	1 Sell rating(s)	1 Hold rating(s)	17 Buy rating(s)	3 Strong Buy rating(s)	3.00

In the previous week, Revolution Medicines had 4 more articles in the media than BioNTech. MarketBeat recorded 8 mentions for Revolution Medicines and 4 mentions for BioNTech. BioNTech's average media sentiment score of 1.23 beat Revolution Medicines' score of 0.34 indicating that BioNTech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioNTech	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Revolution Medicines	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

BioNTech has a beta of 1.33, suggesting that its stock price is 33% more volatile than the broader market. Comparatively, Revolution Medicines has a beta of 1.4, suggesting that its stock price is 40% more volatile than the broader market.

Revolution Medicines has lower revenue, but higher earnings than BioNTech. Revolution Medicines is trading at a lower price-to-earnings ratio than BioNTech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioNTech	$3.25B	7.11	-$1.29B	-$5.88	N/A
Revolution Medicines	$11.58M	3,342.85	-$1.13B	-$7.07	N/A

Summary

Revolution Medicines beats BioNTech on 9 of the 17 factors compared between the two stocks.

How does BioNTech compare to BeOne Medicines?

BioNTech (NASDAQ:BNTX) and BeOne Medicines (NASDAQ:ONC) are both large-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, dividends, profitability, media sentiment, institutional ownership and valuation.

In the previous week, BeOne Medicines had 9 more articles in the media than BioNTech. MarketBeat recorded 13 mentions for BeOne Medicines and 4 mentions for BioNTech. BioNTech's average media sentiment score of 1.23 beat BeOne Medicines' score of 0.18 indicating that BioNTech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioNTech	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BeOne Medicines	3 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

15.5% of BioNTech shares are held by institutional investors. Comparatively, 48.6% of BeOne Medicines shares are held by institutional investors. 19.2% of BioNTech shares are held by company insiders. Comparatively, 6.2% of BeOne Medicines shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

BioNTech has a beta of 1.33, suggesting that its stock price is 33% more volatile than the broader market. Comparatively, BeOne Medicines has a beta of 0.49, suggesting that its stock price is 51% less volatile than the broader market.

BioNTech presently has a consensus price target of $129.56, indicating a potential upside of 42.03%. BeOne Medicines has a consensus price target of $390.00, indicating a potential upside of 39.34%. Given BioNTech's higher probable upside, research analysts clearly believe BioNTech is more favorable than BeOne Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioNTech	1 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.74
BeOne Medicines	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.93

BeOne Medicines has higher revenue and earnings than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioNTech	$3.25B	7.11	-$1.29B	-$5.88	N/A
BeOne Medicines	$5.34B	5.75	$286.93M	$4.47	62.62

BeOne Medicines has a net margin of 8.94% compared to BioNTech's net margin of -44.39%. BeOne Medicines' return on equity of 12.06% beat BioNTech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioNTech	-44.39%	-5.30%	-4.62%
BeOne Medicines	8.94%	12.06%	6.69%

Summary

BeOne Medicines beats BioNTech on 11 of the 17 factors compared between the two stocks.

Get BioNTech News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BNTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BNTX vs. The Competition

Export

Metric	BioNTech	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$23.07B	$3.63B	$7.05B	$12.19B
Dividend Yield	N/A	2.21%	2.66%	6.11%
P/E Ratio	-15.51	21.56	26.13	24.16
Price / Sales	7.11	334.26	555.66	102.80
Price / Cash	68.32	62.10	29.09	36.93
Price / Book	0.94	8.31	10.78	6.38
Net Income	-$1.29B	$23.92M	$3.58B	$337.00M
7 Day Performance	0.36%	3.42%	2.22%	0.10%
1 Month Performance	-2.38%	0.39%	-0.09%	-1.28%
1 Year Performance	-14.52%	65.22%	34.39%	27.68%

BioNTech Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BNTX BioNTech	4.268 of 5 stars	$91.22 +1.4%	$129.56 +42.0%	-14.5%	$23.07B	$3.25B	N/A	7,807	Positive News
ARGX argenex	4.1915 of 5 stars	$903.75 +3.0%	$1,019.50 +12.8%	+58.4%	$54.58B	$4.25B	40.24	1,863	News Coverage Analyst Forecast
TAK Takeda Pharmaceutical	2.529 of 5 stars	$15.46 -1.1%	N/A	+5.4%	$49.74B	$28.32B	39.63	47,455	News Coverage Analyst Downgrade
TEVA Teva Pharmaceutical Industries	4.8566 of 5 stars	$32.25 +2.4%	$41.78 +29.6%	+98.4%	$36.20B	$17.26B	24.24	33,950	Positive News Options Volume
RVMD Revolution Medicines	1.6462 of 5 stars	$165.81 +1.7%	$123.72 -25.4%	+393.3%	$34.65B	$11.58M	N/A	250	Insider Trade Options Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BNTX) was last updated on 6/28/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BioNTech (BNTX) Competitors

BNTX vs. ARGX, TAK, TEVA, RVMD, and ONC

How does BioNTech compare to argenex?

Summary

How does BioNTech compare to Takeda Pharmaceutical?

Summary

How does BioNTech compare to Teva Pharmaceutical Industries?

Summary

How does BioNTech compare to Revolution Medicines?

Summary

How does BioNTech compare to BeOne Medicines?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BNTX vs. The Competition

BioNTech Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

BioNTech (BNTX) Competitors

BNTX vs. ARGX, TAK, TEVA, RVMD, and ONC

How does BioNTech compare to argenex?

Does the media favor ARGX or BNTX?

Which has more volatility & risk, ARGX or BNTX?

Do analysts prefer ARGX or BNTX?

Is ARGX or BNTX more profitable?

Which has stronger valuation and earnings, ARGX or BNTX?

Do insiders and institutionals believe in ARGX or BNTX?

Summary

How does BioNTech compare to Takeda Pharmaceutical?

Do analysts prefer BNTX or TAK?

Which has preferable earnings & valuation, BNTX or TAK?

Which has more volatility and risk, BNTX or TAK?

Is BNTX or TAK more profitable?

Do insiders & institutionals believe in BNTX or TAK?

Does the media prefer BNTX or TAK?

Summary

How does BioNTech compare to Teva Pharmaceutical Industries?

Is BNTX or TEVA more profitable?

Which has more volatility and risk, BNTX or TEVA?

Does the media refer more to BNTX or TEVA?

Do analysts recommend BNTX or TEVA?

Which has preferable valuation and earnings, BNTX or TEVA?

Do institutionals and insiders hold more shares of BNTX or TEVA?

Summary

How does BioNTech compare to Revolution Medicines?

Do insiders & institutionals have more ownership in BNTX or RVMD?

Is BNTX or RVMD more profitable?

Do analysts recommend BNTX or RVMD?

Does the media prefer BNTX or RVMD?

Which has more volatility & risk, BNTX or RVMD?

Which has better earnings and valuation, BNTX or RVMD?

Summary

How does BioNTech compare to BeOne Medicines?

Does the media prefer BNTX or ONC?

Do institutionals and insiders have more ownership in BNTX or ONC?

Which has more risk and volatility, BNTX or ONC?

Do analysts prefer BNTX or ONC?

Which has higher valuation and earnings, BNTX or ONC?

Is BNTX or ONC more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BNTX vs. The Competition

BioNTech Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools